Monopar Therapeutics 8-K

What Happened

• Monopar Therapeutics (NASDAQ: MNPR) announced its financial results for the quarter ended March 31, 2026 via a press release dated May 14, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8‑K (Accession No. 0001437749-26-016981) filed the same day under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 14, 2026 (Form 8‑K).
• Quarter covered: Quarter ended March 31, 2026.
• Exhibit: Press release attached as Exhibit 99.1.
• SEC items reported: Item 2.02 (results of operations and financial condition) and Item 9.01 (exhibits, including the press release and Inline XBRL cover page).

Why It Matters

• This 8‑K notifies investors that Monopar has released its latest quarterly results and related commentary; those details (revenue, net income/loss, cash position, and operational updates) will be in the attached press release. Retail investors should read Exhibit 99.1 to assess the company’s recent performance and any near‑term implications for the business or financial condition.